

	Het	denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA ₂ , OA, COOA, CN, -(CH ₂) _p -Ar, -(CH ₂) _q -OH, -(CH ₂) _p -Het ¹ or carbonyl oxygen (=O),
5	Het ¹	denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A or carbonyl oxygen (=O),
10	Het ²	denotes a monocyclic aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,
15	Het ³	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono- or disubstituted by A,
20	Het ⁴	denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, CONH ₂ , CONHA, CONA ₂ or Ar ² ,
25	Ar ²	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH ₂ , NO ₂ , CN, COOH, COOA, CONH ₂ , NHCOA, NHCONH ₂ , NHSO ₂ A, CHO, COA, SO ₂ NH ₂ or SO ₂ A,
30	R ⁷ , R ⁸ , R ⁹ , R ¹⁰	each, independently of one another, denote H, A or -(CH ₂) _p -Ar,
35	A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
	m	denotes 0, 1, 2, 3 or 4,
	n	denotes 0 or 1,
	p	denotes 0, 1, 2, 3 or 4,
	q	denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,

and, if X = C,

5 R¹ and R² together may also denote -(CH₂)₄- or
R² and R³ together may also denote -(CHR⁷-CHR⁸-NR⁹-
CHR¹⁰)-,

10 and, if Ar¹ denotes piperazinediyl, R⁶ may also denote H or alkyl hav-
ing 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts
and stereoisomers thereof, including mixtures thereof in all ratios.

15 2. Compounds according to Claim 1 in which

R¹ denotes A, OH, NH₂, -(CH₂)_m-Ar or -(CH₂)_m-Het²,

Ar denotes phenyl which is unsubstituted or mono-, di- or
trisubstituted by Hal, A, OA, COOH or COOA,

20 m denotes 0,

and pharmaceutically usable derivatives, solvates, tautomers, salts
and stereoisomers thereof, including mixtures thereof in all ratios.

3. Compounds according to Claim 1 or 2 in which

25 R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,

s denotes 0 or 1,

n denotes 1,

Ar¹ denotes phenylene,

30 R⁶ denotes Het⁴,

Y denotes O,

Het⁴ denotes pyridyl which is unsubstituted or monosubsti-
tuted by CONHA,

or benzo-1,2,5-thiadiazol-5-yl,

35 and pharmaceutically usable derivatives, solvates, tautomers, salts
and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to one or more of Claims 1-3 in which

5 R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,
 s denotes 1,
 n denotes 0,
 Y denotes (CH₂)_q,
 q denotes 0,
 R⁶ denotes Het⁴,
10 Het⁴ denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole,
 1,2,3-triazole, thienyl or furyl, each of which is unsubsti-
 tuted or monosubstituted by CONHA, A and/or Ar²,
 Ar² denotes phenyl which is unsubstituted or mono-, di- or
15 trisubstituted by A,
 and pharmaceutically usable derivatives, solvates, tautomers, salts
 and stereoisomers thereof, including mixtures thereof in all ratios.

5. Compounds according to one or more of Claims 1-4 in which

20 R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,
 s denotes 0,
 n denotes 0,
 Y denotes (CH₂)_q,
25 q denotes 0,
 R⁶ denotes -(CH₂)_r-NH₂, -(CH₂)_r-NHA or -(CH₂)_r-NA₂,
 r denotes 1, 2, 3 or 4,
 and pharmaceutically usable derivatives, solvates, tautomers, salts
30 and stereoisomers thereof, including mixtures thereof in all ratios.

6. Compounds according to one or more of Claims 1-5 in which

35 R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,
 s denotes 0,
 n denotes 1,
 Ar¹ denotes phenylene,

Y denotes O, $(\text{CH}_2)_q$ or NH,
R⁶ denotes $-(\text{CH}_2)_r\text{NH}_2$, $-(\text{CH}_2)_r\text{NHA}$ or $-(\text{CH}_2)_r\text{NA}_2$,
q denotes 0, 1, 2, 3 or 4,
r denotes 0, 1, 2, 3 or 4,
5 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

7. Compounds according to one or more of Claims 1-6 in which

10 R⁴ denotes $-(\text{CH}_2)_s-(\text{Ar}^1)_n\text{Y-R}^6$,
s denotes 1, 2, 3 or 4,
n denotes 0,
Y denotes $(\text{CH}_2)_q$,
15 q denotes 0,
R⁶ denotes Het⁴,
Het⁴ denotes a monocyclic saturated heterocycle having 1 to 2 N and/or O atoms, which may be unsubstituted or mono- or disubstituted by A,
20 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

8. Compounds according to one or more of Claims 1-7 in which

25 R¹ denotes A, OH, NH₂, $-(\text{CH}_2)_m\text{Ar}$,
m denotes 0,
Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
30 R² if X = N is absent or
if X = C denotes CN,
R³ denotes H, A, -S-A, phenyl or $-(\text{CH}_2)_p\text{-Het}$,
and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
35

9. Compounds according to one or more of Claims 1-8 in which

5 R¹ denotes A, OH, NH₂, -(CH₂)_m-Ar,
 m denotes 0,
 Ar denotes phenyl which is unsubstituted or mono-, di- or
 trisubstituted by Hal, A, OA, COOH or COOA,
10 R² if X = N is absent or
 if X = C denotes CN,
 R³ denotes H, A, -S-A, phenyl or -(CH₂)_p-Het,
 R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,
15 s denotes 0,
 n denotes 0,
 Y denotes (CH₂)_q,
 q denotes 0,
 R⁶ denotes -(CH₂)_r-NH₂, -(CH₂)_r-NHA or -(CH₂)_r-NA₂,
 r denotes 1, 2, 3 or 4,
 and pharmaceutically usable derivatives, solvates, tautomers, salts
 and stereoisomers thereof, including mixtures thereof in all ratios.

20 10. Compounds according to one or more of Claims 1-9 in which
 R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,
 s denotes 0,
 n denotes 1,
25 Y denotes (CH₂)_q,
 q denotes 0,
 R⁶ denotes -(CH₂)_r-NH₂, -(CH₂)_r-NHA or -(CH₂)_r-NA₂,
 r denotes 0,
30 and pharmaceutically usable derivatives, solvates, tautomers, salts
 and stereoisomers thereof, including mixtures thereof in all ratios.

35 11. Compounds according to one or more of Claims 1-10 in which
 R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,
 s denotes 0,
 n denotes 0 or 1,

Y denotes $(CH_2)_q$,
q denotes 0,
R⁶ denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
r denotes 0, 1, 2, 3 or 4,
5 and pharmaceutically usable derivatives, solvates, tautomers, salts
and stereoisomers thereof, including mixtures thereof in all ratios.

12. Compounds according to one or more of Claims 1-11 in which

10 R⁴ denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s denotes 0,
n denotes 0 or 1,
Y denotes $(CH_2)_q$,
15 R⁶ denotes $-(CH_2)_r-NH_2$, $-(CH_2)_r-NHA$ or $-(CH_2)_r-NA_2$,
Ar¹ denotes phenylene,
Y denotes O, $(CH_2)_q$ or NH,
q denotes 0, 1, 2, 3 or 4,
20 r denotes 0, 1, 2, 3 or 4,
and pharmaceutically usable derivatives, solvates, tautomers, salts
and stereoisomers thereof, including mixtures thereof in all ratios.

13. Compounds according to one or more of Claims 1-12 in which

25 R¹ denotes A, OH, NH₂, $-(CH_2)_m-Ar$,
m denotes 0,
Ar denotes phenyl which is unsubstituted or mono-, di- or
trisubstituted by Hal, A, OA, COOH or COOA,
30 R² if X = N is absent or
if X = C denotes CN,
R³ denotes H, A, -S-A, phenyl or $-(CH_2)_p-Het$,
R⁴ denotes $-(CH_2)_s-(Ar^1)_n-Y-R^6$,
s denotes 0,
35 n denotes 0 or 1,
Y denotes $(CH_2)_q$,

R ⁶	denotes -(CH ₂) _r NH ₂ , -(CH ₂) _r -NHA or -(CH ₂) _r -NA ₂ ,
Ar ¹	denotes phenylene,
Y	denotes O, (CH ₂) _q or NH,
q	denotes 0, 1, 2, 3 or 4,
r	denotes 0, 1, 2, 3 or 4,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10 14. Compounds according to one or more of Claims 1-13 in which

R¹ denotes A, OH, NH₂, -(CH₂)_m-Ar,
m denotes 0,
Ar denotes phenyl which is unsubstituted or mono-, di- or
trisubstituted by Hal, A, OA, COOH or COOA,

15 R² if X = N is absent or
if X = C denotes CN,
R³ denotes H, A, -S-A, phenyl or -(CH₂)_p-Het,
R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,
s denotes 0,
n denotes 1,
Ar¹ denotes phenylene,
R⁶ denotes Het⁴,
Y denotes O,
Het⁴ denotes pyridyl which is unsubstituted or monosubstituted by CONHA,
or benzo-1,2,5-thiadiazol-5-yl,
and pharmaceutically usable derivatives, solvates, tautomers, salts
and stereoisomers thereof, including mixtures thereof in all ratios.

30


15. Compounds according to one or more of Claims 1-14 in which

35 R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,
s denotes 0 or 1,
n denotes 0 or 1,

Y denotes O or $(\text{CH}_2)_q$,
 q denotes 0,
 R⁶ denotes Het⁴,
 Het⁴ denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole,
 5 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar²,
 Ar² denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
 10 Ar¹ denotes phenylene,
 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

15 16. Compounds according to one or more of Claims 1-15 in which
 Het denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA₂, COOA, benzyl, $-(\text{CH}_2)_l\text{-OH}$ or
 20 $-(\text{CH}_2)_p\text{-Het}^1$,
 Het¹ denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms,

25




30

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

35

17. Compounds according to one or more of Claims 1-16 in which
 Het denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA₂, COOA, benzyl, $-(\text{CH}_2)_l\text{-OH}$ or $-(\text{CH}_2)_p\text{-Het}^1$,

Het¹ denotes morpholinyl, pyrrolidinyl, pyridyl



5

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10 18. Compounds according to one or more of Claims 1-17 in which

R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,

s denotes 0 or 1,

n denotes 0 or 1,

Y denotes O, (CH₂)_q or NH,

15 Ar¹ denotes phenylene,

q denotes 0, 1, 2, 3 or 4,

R⁶ denotes Het⁴, -(CH₂)_rNH₂, -(CH₂)_r-NHA or -(CH₂)_r-NA₂,

r denotes 0, 1, 2, 3 or 4,

20 Het⁴ denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, thiazole, 1,2,3-triazole, thienyl or furyl, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar²,

Ar² denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

25 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

30 19. Compounds according to one or more of Claims 1-18 in which

R¹ denotes A, OH, NH₂, -(CH₂)_m-Ar,

m denotes 0,

Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,

35 R² if X = N is absent or


if X = C

denotes CN,

5 R³ denotes H, A, -S-A, phenyl or -(CH₂)_p-Het,

Het denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA₂, COOA, benzyl, -(CH₂)_l-OH or -(CH₂)_p-Het¹,

10 Het¹ denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms,



and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

20 20. Compounds according to one or more of Claims 1-19 in which

R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,

s denotes 0, 1, 2, 3 or 4,

n denotes 0 or 1,

25 Y denotes O or (CH₂)_q,

Ar¹ denotes phenylene,

q denotes 0,

R⁶ denotes Het⁴, -(CH₂)_rNH₂, -(CH₂)_r-NHA or -(CH₂)_r-NA₂,

30 r denotes 0, 1, 2, 3 or 4,

Het⁴ denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, CONH₂, CONHA, CONA₂ or Ar²,

35 Ar² denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.


21. Compounds according to one or more of Claims 1-20 in which
5 Het⁴ denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar²,

10 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

22. Compounds according to one or more of Claims 1-21 in which
15 R⁴ denotes 4-(pyridin-4-yloxy)phenyl, 4-(pyridin-4-yloxy)-phenylmethyl or 4-(benzo-1,2,5-thiadiazol-5-yloxy)-phenyl, where the pyridine radical may be substituted by CONHCH₃,


20 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

23. Compounds according to one or more of Claims 1-22 in which
25 Het¹ denotes an unsubstituted monocyclic saturated or aromatic heterocycle having 1 to 2 N and/or O atoms,



30 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

24. Compounds according to one or more of Claims 1-23 in which
35 Het¹ denotes morpholinyl, pyrrolidinyl, piperidinyl, pyridyl



5 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

10 25. Compounds according to one or more of Claims 1-24 in which Het² denotes an unsubstituted monocyclic aromatic hetero-
cycle having 1-2 N, O and/or S atoms,
and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

15 26. Compounds according to one or more of Claims 1-25 in which R¹ denotes A, OH, NH₂, -(CH₂)_m-Ar or -(CH₂)_m-Het²,
m denotes 0,
20 Ar denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OA, COOH or COOA,
R² if X = N is absent or

if X = C
denotes H, CN, COOA or phenyl,
25 R³ denotes H, A, -S-A, phenyl, NH-benzyl, -(CH₂)_p-Het,
NH-(CH₂)_p-Het, NA₂, NH-alkylene-NA₂ or
NA-alkylene-NA₂,


30 and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

27. Compounds according to one or more of Claims 1-26 in which R² if X = N is absent or
if X = C
35 denotes H, CN, (CH₂)_oAr", (CH₂)_oCOOA or SO₂A,

Ar" denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal or OA,
o denotes 0 or 1,
and pharmaceutically usable derivatives, solvates, tautomers, salts
5 and stereoisomers thereof, including mixtures thereof in all ratios.

28. Compounds according to one or more of Claims 1-27 in which
R¹ denotes A, OH, NH₂, -(CH₂)_m-Ar' or -(CH₂)_m-Het²,
10 Ar' denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, OA, A or COOA,
m denotes 0,
Het² denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or
15 pyridyl,
and pharmaceutically usable derivatives, solvates, tautomers, salts
and stereoisomers thereof, including mixtures thereof in all ratios.

29. Compounds according to one or more of Claims 1-28 in which
20 X denotes C or N,
B denotes N, CH or C-CN,
R¹ denotes A, OH, NH₂, -(CH₂)_m-Ar' or -(CH₂)_m-Het²,
Ar' denotes phenyl which is unsubstituted or mono-, di- or
25 trisubstituted by Hal, OA, A or COOA,
m denotes 0,
Het² denotes thienyl, furyl, imidazolyl, pyrrolyl, thiazolyl or
pyridyl,
30 R² if X = N is absent or
if X = C
denotes H, CN, (CH₂)_oAr", (CH₂)_oCOOA or SO₂A,
Ar" denotes phenyl which is unsubstituted or mono-, di- or
35 trisubstituted by Hal or OA,
o denotes 0 or 1,

	R^3	denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$ -Het, NH- $(CH_2)_p$ -Het, NA ₂ , NH-alkylene-NA ₂ or NA-alkylene-NA ₂ ,
5	Het	denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA ₂ , COOA, benzyl, $-(CH_2)_l$ -OH or $-(CH_2)_p$ -Het ¹ ,
10	Het ¹	denotes morpholinyl, pyrrolidinyl, pyridyl
		or 
15	R^4	denotes $-(CH_2)_s$ - $(Ar^1)_n$ -Y-R ⁶ ,
	Y	denotes O or $(CH_2)_q$,
	R^5	denotes H or CH ₃ ,
20	R^4 and R^5	together also denote Het ⁴ -N $\begin{array}{c} CH_2-CH_2- \\ \\ CH_2-CH_2- \end{array}$,
	R^6	denotes Het ⁴ , $-(CH_2)_r$ -NH ₂ , $-(CH_2)_r$ -NHA or $-(CH_2)_r$ -NA ₂ ,
25	Het ⁴	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar ² ,
	Ar ¹	denotes phenylene or piperazinediyl,
	Ar ²	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
30	R^7, R^8, R^9, R^{10}	each, independently of one another, denote H, A or $-(CH_2)_p$ -Ar,
	A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
	n	denotes 0 or 1,
35	p	denotes 0, 1, 2, 3 or 4,
	q	denotes 0, 1, 2, 3 or 4,

5
r denotes 0, 1, 2, 3 or 4,
s denotes 0, 1, 2, 3 or 4,
t denotes 1, 2, 3 or 4,
Hal denotes F, Cl, Br or I,

and, if X = C,


R¹ and R² together may also denote -(CH₂)₄- or
R² and R³ together may also denote -(CHR⁷-NR⁸-CHR⁹-
10 CHR¹⁰)-,

and, if Ar¹ denotes piperazinediyl, R⁶ may also denote H or alkyl hav-
ing 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts
15 and stereoisomers thereof, including mixtures thereof in all ratios.

30. Compounds according to one or more of Claims 1-29 in which

X denotes C or N,
20 B denotes N, CH or C-CN,
R¹ denotes A, OH, NH₂, -(CH₂)_m-Ar' or -(CH₂)_m-Het²,
Ar' denotes phenyl which is unsubstituted or mono-, di- or
trisubstituted by Hal, OA, A or COOA,
m denotes 0,
25 Het² denotes an unsubstituted monocyclic aromatic hetero-
cycle having 1-2 N, O and/or S atoms,
R² if X = N is absent or
if X = C
30 denotes H, CN, (CH₂)_oAr'', (CH₂)_oCOOA or SO₂A,
Ar'' denotes phenyl which is unsubstituted or mono-, di- or
trisubstituted by Hal or OA,
o denotes 0 or 1,
35 R³ denotes H, A, -S-A, phenyl, NH-benzyl, -(CH₂)_p-Het,
NH-(CH₂)_p-Het, NA₂, NH-alkylene-NA₂ or
NA-alkylene-NA₂,

5	Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, NHA, NA ₂ , COOA, benzyl, -(CH ₂) _l -OH or -(CH ₂) _p -Het ¹ ,
10	Het ¹	denotes morpholinyl, pyrrolidinyl, pyridyl
		or 
15	R ⁴	denotes -(CH ₂) _s -(Ar ¹) _n -Y-R ⁶ ,
	Y	denotes O or (CH ₂) _q ,
20	R ⁵	denotes H or CH ₃ ,
	R ⁴ and R ⁵	together also denote Het ⁴ —N(CH ₂ -CH ₂) ₂ —CH ₂ -CH ₂ —,
25	R ⁶	denotes Het ⁴ , -(CH ₂) _r -NH ₂ , -(CH ₂) _r -NHA or -(CH ₂) _r -NA ₂ ,
	Het ⁴	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by A, CONH ₂ , CONHA, CONA ₂ or Ar ² ,
	Ar ¹	denotes phenylene or piperazinediyl,
30	Ar ²	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
	R ⁷ , R ⁸ , R ⁹ , R ¹⁰	each, independently of one another, denote H, A or -(CH ₂) _p -Ar,
	A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
	n	denotes 0 or 1,
	p	denotes 0, 1, 2, 3 or 4,
35	q	denotes 0, 1, 2, 3 or 4,
	r	denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,
 t denotes 1, 2, 3 or 4,
 Hal denotes F, Cl, Br or I,

5

and, if X = C,

R¹ and R² together may also denote -(CH₂)₄- or
 R² and R³ together may also denote -(CHR⁷-NR⁸-CHR⁹-
 CHR¹⁰)-,

10


and, if Ar¹ denotes piperazinediyl, R⁶ may also denote H or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

15

31. Compounds according to one or more of Claims 1-30 in which


X denotes N,
 B denotes N, CH or C-CN,
 R¹ denotes NH₂,
 20 R² is absent,
 R³ denotes H, A, -S-A, phenyl, NH-benzyl, -(CH₂)_p-Het, NH-(CH₂)_p-Het, NA₂, NH-alkylene-NA₂ or NA-alkylene-NA₂,
 25 Het denotes piperazinyl, piperidinyl, morpholinyl, pyrrolidinyl, pyridyl or furyl, which are unsubstituted or may be mono-, di- or trisubstituted by Hal, A, NHA, NA₂, COOA, benzyl, -(CH₂)_t-OH or -(CH₂)_p-Het¹,
 30 Het¹ denotes morpholinyl, pyrrolidinyl, pyridyl



35

R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,

Y	denotes O or $(CH_2)_q$,
R^5	denotes H or CH_3 ,
R^4 and R^5	together also denote $Het^4 - N \begin{array}{c} CH_2-CH_2- \\ \backslash \quad / \\ CH_2-CH_2- \end{array}$,
5	
R^6	denotes Het^4 , $-(CH_2)_rNH_2$, $-(CH_2)_rNHA$ or $-(CH_2)_rNA_2$,
Het^4	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or
10	monosubstituted by $CONHA$, A and/or Ar^2 ,
Ar^1	denotes phenylene or piperazinediyl,
Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A ,
15	
A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
n	denotes 0 or 1,
p	denotes 0, 1, 2, 3 or 4,
q	denotes 0, 1, 2, 3 or 4,
20	
r	denotes 0, 1, 2, 3 or 4,
s	denotes 0, 1, 2, 3 or 4,
t	denotes 1, 2, 3 or 4,
Hal	denotes F, Cl, Br or I,
25	and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms,
	and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.
30	
32.	Compounds according to one or more of Claims 1-31 in which
	X denotes N,
	B denotes N, CH or C-CN,
	R^1 denotes NH_2 ,
35	R^2 is absent,

	R^3	denotes H, A, -S-A, phenyl, NH-benzyl, $-(CH_2)_p$ -Het, NH- $(CH_2)_p$ -Het, NA ₂ , NH-alkylene-NA ₂ or NA-alkylene-NA ₂ ,
5	Het	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N and/or O atoms, which may be unsub- stituted or mono-, di- or trisubstituted by Hal, A, NHA, NA ₂ , COOA, benzyl, $-(CH_2)_t$ -OH or $-(CH_2)_p$ -Het ¹ ,
10	Het ¹	denotes morpholinyl, pyrrolidinyl, pyridyl
		or 
15	R^4	denotes $-(CH_2)_s$ - $(Ar^1)_n$ -Y-R ⁶ ,
	Y	denotes O or $(CH_2)_q$,
	R^5	denotes H or CH ₃ ,
20	R^4 and R^5	together also denote Het ⁴ -N $\begin{array}{c} CH_2-CH_2- \\ \\ CH_2-CH_2- \end{array}$,
	R^6	denotes Het ⁴ , $-(CH_2)_r$ -NH ₂ , $-(CH_2)_r$ -NHA or $-(CH_2)_r$ -NA ₂ ,
25	Het ⁴	denotes a monocyclic saturated or aromatic heterocycle having 1 to 3 N, O and/or S atoms, which may be unsub- stituted or mono-, di- or trisubstituted by A, CONH ₂ , CONHA, CONA ₂ or Ar ² ,
	Ar ¹	denotes phenylene or piperazinediyl,
30	Ar ²	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
	A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
	n	denotes 0 or 1,
35	p	denotes 0, 1, 2, 3 or 4,
	q	denotes 0, 1, 2, 3 or 4,

r denotes 0, 1, 2, 3 or 4,

s denotes 0, 1, 2, 3 or 4,

t denotes 1, 2, 3 or 4,

Hal denotes F, Cl, Br or I,




5 and, if Ar¹ denotes piperazinediyl, R⁶ may also denote H or alkyl having 1-6 C atoms,

and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.


10

33. Compounds according to Claim 1, selected from the group

15 (7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)phenyl]amine,



35



15 (7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

20 (7-methyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[3-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

25 (5,7-bistrifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(2-(N-methylaminocarbonyl)pyridin-4-yloxy)phenyl]amine,

(5,7-dimethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

30 (7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]amine,

35 (2-phenylthiazol-4-ylmethyl)-(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

(2-phenylthiazol-4-ylmethyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,




(7-phenyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)-[4-(pyridin-4-yloxy)benzyl]amine,

5 (3-dimethylaminopropyl)-(7-methyl-5-trifluoromethyl-1,2,4-triazolo[1,5-a]pyrimidin-2-yl)amine,

7-phenyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,


10 7-methyl-2-[4-(pyridin-4-yloxy)phenylamino]-5-trifluoromethyl-pyrazolo[1,5-a]pyrimidine-3-carbonitrile,

15 7-phenyl-2-[4-(pyridin-4-yloxy)phenylmethylamino]-5-trifluoromethylpyrazolo[1,5-a]pyrimidine-3-carbonitrile,




35


5




10




15



20



25




30


6-benzyl-2-[3-(4-methylpiperazin-1-yl)propylamino]-5,6,7,8-tetrahydro-1,3,3a,6,9-pentaaazacyclopenta[b]naphthalen-4-ol,

35


5




10



15




20




25


30




35




5




10




15





20





25














5




10




15





20




25









5




10




15



20




25




30

35


5




10



15




20




25


30




35




5




10




15




20




5




10




15



20




25




30


35




5




10




15




20




30




5




10



15




20




25


5




10




15




20



25




30




35


5



10




15




20

25




30


35




5




10




15



20




25




30


5




10




15




20




25




30




5




10




15



20




25



30

5



10




15


20

25


30

35







5




10




15




20




30




35




5




10




15




20




25




5




10




15




20




25



30



5



and pharmaceutically usable derivatives, solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.


10

34. Process for the preparation of compounds of the formula I according to Claims 1-33 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, characterised in that

a) for the preparation of compounds of the formula I
in which X denotes C, a compound of the formula II

15

20




in which R^4 , R^5 and B have the meanings indicated in Claim 1,

25

i) is reacted with a compound of the formula IIIa

30



35


in which R^1 OA and
 R^2 and R^3 have the meanings indicated in Claim 1,

or

ii) with a compound of the formula IIIb

5

10



in which R^1 , R^2 and R^3 have the meanings indicated in Claim 1,
and A denotes alkyl having 1, 2, 3 or 4 C atoms,


15

or

iii) with a compound of the formula IIIc

20

25



in which

30 R^1 , besides the meanings indicated in Claim 1, also denotes OA,
 R^2 and R^3 have the meanings indicated in Claim 1,
and A, A' each, independently of one another, denote alkyl having 1,
2, 3 or 4 C atoms,
35 or A and A' together may also form a butylene or pentylene chain,

or


5 b) for the preparation of compounds of the formula I
 in which X denotes N and R¹ denotes NH₂,
 a compound of the formula II is reacted with a compound of the formula IIId



15 in which R³ has the meaning indicated in Claim 1,
 and A denotes alkyl having 1, 2, 3 or 4 C atoms,

or

20 c) for the preparation of compounds of the formula I in which
 X denotes N,
 R¹ denotes H, A, -(CH₂)_m-Ar or -(CH₂)_m-Het²,
 R³ denotes -S-A
 25 a compound of the formula II is reacted with a compound of the formula IIle



in which

35 R¹ denotes H, A, -(CH₂)_m-Ar or -(CH₂)_m-Het²
 and A denotes alkyl having 1, 2, 3 or 4 C atoms,

and/or that one or more radical(s) R¹,R² and/or R³ in a compound of the formula I is (are) converted into one or more radical(s) R¹,R² and/or R³,

5

by, for example,

- i) converting an alkylsulfanyl group into an amine,
- ii) hydrolysing an ester to the acid, reducing it to the aldehyde or alcohol,
- 10 iii) reducing a nitrile to the aldehyde or amine,

and/or

a base or acid of the formula I is converted into one of its salts.

15

35. Medicaments comprising at least one compound of the formula I according to Claim 1 and/or pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.
- 20
36. Use of compounds according to Claim 1 and pharmaceutically usable derivatives, salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of kinase signal transduction plays a role.
- 25
30. 37. Use according to Claim 36, where the kinases are selected from the group of the tyrosine kinases.
- 35
38. Use according to Claim 37, where the tyrosine kinases are TIE-2, VEGFR, PDGFR, FGFR and/or FLT/KDR.

5 39. Use according to Claim 37 of compounds according to Claim 1, and pharmaceutically usable derivatives, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of tyrosine kinases by the compounds according to Claim 1.

10 40. Use according to Claim 39 for the preparation of a medicament for the treatment of diseases which are influenced by inhibition of TIE-2, VEGFR, PDGFR, FGFR and/or FLT/KDR by the compounds according to Claim 1.

15 41. Use according to Claim 39 or 40, where the disease to be treated is a solid tumour.

20 42. Use according to Claim 41, where the solid tumour originates from the group of tumours of the squamous epithelium, the bladder, the stomach, the kidneys, of head and neck, the oesophagus, the cervix, the thyroid, the intestine, the liver, the brain, the prostate, the urogenital tract, the lymphatic system, the stomach, the larynx and/or the lung.

25 43. Use according to Claim 41, where the solid tumour originates from the group monocytic leukaemia, lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas and breast carcinoma.

30 44. Use according to Claim 41, where the solid tumour originates from the group of lung adenocarcinoma, small-cell lung carcinomas, pancreatic cancer, glioblastomas, colon carcinoma and breast carcinoma.


35 45. Use according to Claim 39 or 40, where the disease to be treated is a tumour of the blood and immune system.

46. Use according to Claim 45, where the tumour originates from the group of acute myelotic leukaemia, chronic myelotic leukaemia, acute lymphatic leukaemia and/or chronic lymphatic leukaemia.
- 5 47. Use according to Claim 39 or 40 for the treatment of a disease in which angiogenesis is implicated.
- 10 48. Use according to Claim 47, where the disease is an ocular disease.
- 15 49. Use according to Claim 39 or 40 for the treatment of retinal vascularisation, diabetic retinopathy, age-induced macular degeneration and/or inflammatory diseases.
- 20 50. Use according to Claim 49, where the inflammatory disease originates from the group rheumatoid arthritis, psoriasis, contact dermatitis and delayed hypersensitivity reactions.
- 25 51. Use according to Claim 39 or 40 for the treatment of bone pathologies, where the bone pathology originates from the group osteosarcoma, osteoarthritis and rickets.
- 30 52. Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound of the formula I is administered in combination with a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) antiproliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.
- 35

53. Use of compounds of the formula I according to Claim 1 and/or physiologically acceptable salts and solvates thereof for the preparation of a medicament for the treatment of solid tumours, where a therapeutically effective amount of a compound of the formula I is
 5 administered in combination with radiotherapy and a compound from the group 1) oestrogen receptor modulator, 2) androgen receptor modulator, 3) retinoid receptor modulator, 4) cytotoxic agent, 5) anti-proliferative agent, 6) prenyl-protein transferase inhibitor, 7) HMG-CoA
 10 reductase inhibitor, 8) HIV protease inhibitor, 9) reverse transcriptase inhibitor and 10) another angiogenesis inhibitor.

54. Use according to Claim 39 or 40 for the preparation of a medicament
 15 for the treatment of diseases which are based on disturbed TIE-2 activity,
 where a therapeutically effective amount of a compound according to
 Claim 1 is administered in combination with a growth-factor receptor
 20 inhibitor.

55. Intermediate compounds of the formula I-1



in which

30 B denotes N, CH or C-CN,

R⁴ denotes -(CH₂)_s-(Ar¹)_n-Y-R⁶,

R⁵ denotes H or CH₃,

35 R⁴ and R⁵ together also denote Het⁴-N(CH₂-CH₂-CH₂-CH₂-),

R⁶ denotes Het⁴, -(CH₂)_rNH₂, -(CH₂)_rNHA or -(CH₂)_rNA₂,

	Y	denotes O, S, $(\text{CH}_2)_q$ or NH,
	Ar^1	denotes phenylene or piperazinediyl,
5	Het^4	denotes a mono- or bicyclic saturated, unsaturated or aromatic heterocycle having 1 to 4 N, O and/or S atoms, which may be unsubstituted or mono-, di- or trisubstituted by Hal, A, CONH_2 , CONHA , CONA_2 or Ar^2 ,
10	Ar^2	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by Hal, A, OH, OA, NH_2 , NO_2 , CN, COOH, COOA , CONH_2 , NHCOA , NHCONH_2 , NHSO_2A , CHO, COA, SO_2NH_2 or SO_2A ,
15	A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
20	n	denotes 0 or 1,
	q	denotes 0, 1, 2, 3 or 4,
	r	denotes 0, 1, 2, 3 or 4,
	s	denotes 0, 1, 2, 3 or 4,
25	Hal	denotes F, Cl, Br or I, and, if Ar^1 denotes piperazinediyl, R^6 may also denote H or alkyl having 1-6 C atoms, and solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

56. Intermediate compounds according to Claim 55

in which

	B	denotes N, CH or C-CN,
30	R^4	denotes $-(\text{CH}_2)_s-(\text{Ar}^1)_n-\text{Y}-\text{R}^6$,
	Y	denotes O or $(\text{CH}_2)_q$,
	R^5	denotes H or CH_3 ,
35	R^4 and R^5	together also denote $\text{Het}^4-\text{N}(\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{CH}_2-)$,
	R^6	denotes Het^4 , $-(\text{CH}_2)_r-\text{NH}_2$, $-(\text{CH}_2)_r-\text{NHA}$ or $-(\text{CH}_2)_r-\text{NA}_2$,

	Het ⁴	denotes pyridyl, benzo-1,2,5-thiadiazol-5-yl, piperazine, thiazole or imidazole, each of which is unsubstituted or monosubstituted by CONHA, A and/or Ar ² ,
5	Ar ¹	denotes phenylene or piperazinediyl,
	Ar ²	denotes phenyl which is unsubstituted or mono-, di- or trisubstituted by A,
10	A	denotes alkyl having 1 to 10 C atoms, where, in addition, 1-7 H atoms may be replaced by F and/or chlorine,
	n	denotes 0 or 1,
	q	denotes 0, 1, 2, 3 or 4,
	r	denotes 0, 1, 2, 3 or 4,
	s	denotes 0, 1, 2, 3 or 4,
15	Hal	denotes F, Cl, Br or I, and, if Ar ¹ denotes piperazinediyl, R ⁶ may also denote H or alkyl having 1-6 C atoms, and solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
20		

57. Intermediate compounds according to Claim 55 or 56, selected from the group

25 *N*-[4-(pyridin-4-yloxy)phenyl]-4*H*-1,2,4-triazole-3,5-diamine,
 N-{4-[2-(N-methylaminocarbonyl)pyridin-4-yloxy]phenyl}-4*H*-1,2,4-triazole-3,5-diamine,
 N-{3-[2-(N-methylaminocarbonyl)pyridin-4-yloxy]phenyl}-4*H*-1,2,4-triazole-3,5-diamine,
30 *N*-[4-(pyridin-4-yloxy)phenylmethyl]-4*H*-1,2,4-triazole-3,5-diamine,
 N-(5-methyl-2-phenyl-2*H*-1,2,3-triazol-4-ylmethyl)-4*H*-1,2,4-triazole-3,5-diamine,
 N-(2-phenylthiazol-4-ylmethyl)-4*H*-1,2,4-triazole-3,5-diamine,

5 *N*-[4-(2-diethylaminoethoxy)phenyl]-4*H*-1,2,4-triazole-3,5-di-
amine,

10 *N*-[4-(benzo-1,2,5-thiadiazol-5-yloxy)phenyl]-4*H*-1,2,4-triazole-
3,5-diamine,

15 *N*-[4-(pyridin-4-ylsulfanyl)phenyl]-4*H*-1,2,4-triazole-3,5-diamine,
5-amino-3-[4-(pyridin-4-yloxy)phenylamino]-1*H*-pyrazole-4-car-
bonitrile,

20 *N**3*- [4-(pyridin-4-yloxy)phenyl]-1*H*-pyrazole-3,5-diamine,
and solvates, salts, tautomers and stereoisomers thereof, including
mixtures thereof in all ratios.

25

30

35